Bioengineering of a New Antibody Drug Delivery Technology

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$149,050.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43MH083334-01
Award Id:
89357
Agency Tracking Number:
MH083334
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ARMAGEN TECHNOLOGIES, INC., 914 COLORADO AVE, SANTA MONICA, CA, 90401
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
137142589
Principal Investigator:
YUNZHANG
(310) 917-1275
YUNZHANG@ARMAGEN.COM
Business Contact:
() -
rboado@armagen.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Monoclonal antibodies (MAb) are potential new therapeutics for many brain diseases, including Alzheimer's disease (AD), Parkinson's disease, mad cow disease, West Nile encephalitis, neuro-AIDS, brain injury, brain cance r, or multiple sclerosis. In almost all cases, it is necessary that the MAb therapeutic that is administered into the blood be able to access target sites within the brain. However, MAb's are large molecule drugs that do not cross the blood-brain barrier ( BBB). The BBB problem prevents the brain drug development of antibody drugs. The proposed research will develop a new technology for antibody drug delivery to brain, which could also be used for other organs. This work is based on the genetic engineering o f a fusion protein comprised of 2 antibodies. One antibody is the therapeutic antibody, and the other antibody is a drug delivery system. The prototype of this new technology is novel fusion protein, which is created by fusion of a single chain Fv (ScFv) a ntibody to the carboxyl terminus of both heavy chains of a genetically engineered MAb against the human insulin receptor (HIR). The MAb against the HIR does penetrate brain via transport across the BBB on the endogenous insulin receptor. Feasibility studie s show the fusion protein retains its bi-functional properties following genetic engineering and transient expression in COS cells: the fusion antibody both binds the HIR, to enable transport across the BBB in vivo, and binds Abeta plaque, to cause amyloid disaggregation in AD transgenic mouse brain. The purpose of these Phase I studies is (1) genetically engineer a tandem vector expressing the hetero-tetrameric fusion protein, (2) to engineer a permanently transfected host cell line that expresses high lev els of the fusion antibody in serum free medium, (3) to biochemically and functionally characterize the fusion antibody, and (4) determine the plasma pharmacokinetics and brain uptake of the fusion protein in the adult Rhesus monkey. If successful, this re search will develop a new technology for the drug delivery of antibody therapeutics. Public Health Relevance: Monoclonal antibodies are powerful new therapeutic products of biotechnology. Antibody drugs could be applied to many serious brain disorde rs, such as Alzheimer's disease, Parkinson's disease, mad cow disease, West Nile encephalitis, neuro-AIDS, brain injury, brain cancer, or multiple sclerosis. However, antibody drugs cannot be developed for these disorders, because the antibody drugs do not cross the blood-brain barrier (BBB). The present research will develop a new technology for the drug delivery of antibody drugs for the brain, which could be applied to other organs.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government